行情

CBLI

CBLI

克利夫兰生物实验室
NASDAQ

实时行情|Nasdaq Last Sale

0.7051
-0.0050
-0.70%
已收盘, 16:00 12/13 EST
开盘
0.7400
昨收
0.7101
最高
0.7995
最低
0.7012
成交量
1.02万
成交额
--
52周最高
2.160
52周最低
0.5000
市值
869.96万
市盈率(TTM)
-3.6684
分时
5日
1月
3月
1年
5年

EPS

CBLI 新闻

  • The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout
  • Benzinga.11/19 12:56
  • What Kind Of Investor Owns Most Of Cleveland BioLabs, Inc. (NASDAQ:CBLI)?
  • Simply Wall St..11/18 11:58
  • The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
  • Benzinga.11/15 12:08
  • Cleveland BioLabs Q3 EPS $(0.04) Up From $(0.1) YoY
  • Benzinga.11/14 21:34

更多

所属板块

生物技术和医学研究
-0.88%
制药与医学研究
+0.01%

热门股票

名称
价格
涨跌幅

CBLI 简况

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.
展开

Webull提供Cleveland BioLabs, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。